Corporate Profile

Secura Bio^® is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada.

Leadership

Charles (Chip) R. Romp

PRESIDENT & CHIEF EXECUTIVE OFFICER

With over 25 years in the pharmaceutical industry Mr. Romp has proven his ability to build the pharmaceutical commercialization process from development stage to successful global product. He has an extensive background in various therapeutic areas with an emphasis on oncology and hematology. He spent 12 years at Genentech in a wide range of sales, marketing, and development roles spanning their entire oncology/immunology product portfolio. Mr. Romp was previously Executive Vice President, US Commercial at Seagen, Inc. where he was a member of the Executive Committee. He oversaw the entire Seagen Commercial organization in addition to broader roles in corporate communications, investor relations, and business development.

Brett K.E. Lund, JD, MBA

Chief Legal Officer & Chief Operating Officer

Mr. Lund was previously the Chief Legal Officer of Genoptix (acquired by NeoGenomics) and at Gevo (NASDAQ: GEVO). Mr. Lund was the CEO of Agarigen (acquired by Precigen) and held senior positions in Syngenta Biotechnology’s biopharma business. Mr. Lund was previously a corporate attorney at the law firm of Cooley LLP. Mr. Lund was named the “Best Corporate Counsel” by Denver Business Journal, “Forty Under 40” by Denver Business Journal and one of the “Most Influential Young Professionals” by ColoradoBiz Magazine. Mr. Lund served on the Board of TRAX International, Agarigen, Colorado BioScience Association, Colorado Cleantech Industry Association and Gevo Development.

Mr. Lund holds a JD from Duke Law School and an MBA from Duke University’s Fuqua School of Business. He is a Certified Licensing Professional by the Licensing Executives Society and has been admitted to practice law in California and North Carolina.

WILL BROWN, MBA

CHIEF FINANCIAL OFFICER

Mr. Brown is an executive with deep experience in capital markets, accounting, and finance. He formerly was the Chief Financial Officer and Interim Chief Executive Officer of ObsEva SA (NASDAQ: OBSV / SIX: OBSN) where he led the company through a restructuring, successfully generating a >$100 million strategic disposition. He also was the Chief Financial Officer of Altimmune, Inc. (NASDAQ: ALT) where he was critical in the company’s transformation and growth through more than $300 million of new equity issuances and a strategic acquisition. Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs.

Mr. Brown was a CPA (2006 to 2022, AL# 10198), and earned both his MBA and B.S. from Auburn University Montgomery.

Juan Estruch

Head of Corporate Development

Dr. Estruch has over 25 years of experience in Life Sciences and was a co-founder of Secura. He has extensive experience in product assessment, corporate strategy, corporate development and served in increasingly senior management roles. Prior to Secura, Dr. Estruch served in senior positions or as head of corporate development for Ciba-Geigy, Novartis, Diversa, Prometheus and Genoptix. He has a proven track record for identifying under-exploited biopharmaceutical assets that are candidates for repositioning or relaunch.

Dr. Estruch earned a Ph.D. in Biochemistry and Molecular Biology from the University of Essen, Germany and Valencia, Spain. He also earned an MBA from the Fuqua School of Business, Duke University.

David Sidransky, MD

Clinical / Medical Advisor to the CEO

Dr. Sidransky is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer and the development of patient derived models for drug testing. Dr. Sidransky is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He has authored more than 600 peer-reviewed publications, and has contributed to more than 65 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals and Champions Oncology, a developer of precision models for cancer therapy. He is chairman of the board of directors of Ayala and Advaxis and is a member of the BOD of Galmed, Ascentage pharma, and Orgenesis. In addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.

Jamie Sulley, PhD

Senior Vice President — Global Regulatory Affairs, Quality, and Technical Operations

Dr. Sulley has 32 years of experience in biotech and pharmaceutical industry experience. Prior to joining Secura Bio, she was President and Member of the Board of Directors of Tamir Biotechnology (acquired by Orgenesis), Chief Operating Officer of Tensys Medical (acquired by Shanshi), General Manager for Pharmalink Consulting (acquired by Genpact), and former President of TCSI and JASA. She has grown and expanded pharmaceutical and med tech companies providing global leadership and support for FDA, EMA, MHRA and other health agency regulatory activities at the corporate level. Dr. Sulley has brought drug development programs from proof of concept through to global commercialization for New Chemical Entity (NCE), 505(b)(1) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products leveraging her experience as an accredited FDA reviewer. She holds BS and PHD in Chemistry and a Masters in Public Health from University of Liverpool.

Gregory S. Wessels

SENIOR VICE PRESIDENT, COMMERCIAL STRATEGY AND OPERATIONS

Mr. Wessels has over 25 years of life sciences experience in sales, marketing and commercialization strategy, most recently having served as Senior Vice President and Chief Commercial Officer of Aprea Therapeutics. Mr. Wessels also held global and regional hematology/oncology positions of increasing responsibility over more than 10 years at Celgene Corporation, culminating as Executive Director, Lymphoma Global Marketing. Prior to joining Celgene he spent 11 years with Sanofi US in sales, marketing and business planning roles.

Mr. Wessels received a BS in Biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Board Members

Patrick Vink, MD, MBA

Chairman

Dr. Vink brings over 35 years of industry experience and currently serves as Chairman and Board member of several public and private biopharma companies, both in the U.S. and in Europe, including F2G Ltd and Essential Pharma. Throughout his Board tenures, he has played an active role in initial public offerings, achieving meaningful development, regulatory and commercial milestones, and facilitating geographic expansions. As a Board member of Amryt Pharma, he was involved in the recent sale to Chiesi Farmaceutici for over $1.4 billion, and as Chair of the Board of Biognosys, he guided their transaction with Bruker in 2023. Dr. Vink previously served as Executive Vice President and Chief Operating Officer at Cubist, Inc., a leader in the acute care hospital market. In this role, Dr. Vink oversaw all worldwide commercial and technical operations until the successful acquisition of Cubist by Merck for $9.5 billion in 2015. Prior to Cubist, Dr. Vink held several key leadership roles across the biopharmaceutical industry, including head of the Global Hospital Business at Mylan Inc., the Global Hospital Business at Sandoz (a division of Novartis) and the head of the International Business at Biogen. Dr. Vink holds an M.D. from the University of Leiden and an MBA from the University of Rochester.

Charles (Chip) R. Romp

President and CEO, Board Member

With over 25 years in the pharmaceutical industry Mr. Romp has proven his ability to build the pharmaceutical commercialization process from development stage to successful global product. He has an extensive background in various therapeutic areas with an emphasis on oncology and hematology. He spent 12 years at Genentech in a wide range of sales, marketing, and development roles spanning their entire oncology/immunology product portfolio. Mr. Romp was previously Executive Vice President, US Commercial at Seagen, Inc. where he was a member of the Executive Committee. He oversaw the entire Seagen Commercial organization in addition to broader roles in corporate communications, investor relations, and business development.

Jeffrey A. Ferrell

Board Member

Jeffrey A. Ferrell is the founder of Athyrium (2008) and currently serves as the firm’s Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.

Prior to forming Athyrium, Mr. Ferrell served in several capacities at Lehman Brothers, including overseeing life sciences investments for Global Trading Strategies (a principal investment group within Lehman) and as Vice President in Lehman Brothers’ Private Equity division focused on life sciences investments. Prior to joining Lehman in 2001, he was Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. Investments Mr. Ferrell has been involved with include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, Lpath, Auxilium Pharmaceuticals, KaloBios, Fluidigm, and more. Mr. Ferrell graduated with an AB in Biochemical Sciences from Harvard College.

Mr. Ferrell currently serves on the board of Progenity (NASDAQ: PROG).

Joerg Moeller, MD

Board Member

With over 30 years of experience in the pharmaceutical industry, Dr. Moeller has a proven track record of developing and launching innovative and competitive drugs in various therapeutic areas, such as cardiovascular, oncology, hematology, ophthalmology, women’s health, dermatology and infectious diseases. As the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma’s Executive Committee, he has successfully led large global organizations in research, development, and regulatory compliance, and has built growth portfolios through productive and collaborative partnerships with academic institutions, biotech companies, and pharmaceutical peers. Dr. Moeller most recently was the Chief Executive Officer and Executive Board Member of BenevolentAI, a leader in AI augmented drug discovery. Previously, he was the Global Head of Research and Development at LEO Pharma A/S, a leading dermatology company. He is passionate about fostering a culture of excellence, innovation, teamwork, and diversity in his teams and across the industry. He is also an advocate of digitalization and artificial intelligence as drivers of R&D efficiency and quality.